BIO vs LAB · rev $2.58B vs rev $174.4M
BIO (BIO) versus Standard Biotools Inc (LAB) — a side-by-side from cached financials, not a winner call.
BIO (BIO) common stock.
Standard Biotools Inc (LAB) is a medical devices company listed on NASDAQ.
Latest reported BIO revenue for 2025-12-31 was $2.58B. Net income was $759.9M. Revenue was up 0.7% from 2024-12-31 to 2025-12-31. BIO currently screens at market cap $0.
Latest reported LAB revenue for 2024-12-31 was $174.4M. Net income was -$138.9M. Revenue was up 64.0% from 2023-12-31 to 2024-12-31. LAB currently screens at market cap $317.1M.
BIO currently screens at market cap $0. LAB currently screens at market cap $317.1M.
Not investment advice. Open the BIO and LAB stock pages for the full models.
Not investment advice.